170 related articles for article (PubMed ID: 19959412)
1. Drug-drug interactions with raltegravir.
Burger DM
Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):17-21. PubMed ID: 19959412
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
Cabrera C
Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics and interactions of raltegravir].
Placeres Alsina MM; Tuset Creus M; Miró JM
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():23-8. PubMed ID: 19572422
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir in treatment naive patients.
Cossarini F; Castagna A; Lazzarin A
Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):22-9. PubMed ID: 19959413
[TBL] [Abstract][Full Text] [Related]
5. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
7. Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.
Reynolds HE; Chrdle A; Egan D; Chaponda M; Else L; Chiong J; Back DJ; Khoo SH
J Antimicrob Chemother; 2015 Feb; 70(2):550-4. PubMed ID: 25261424
[TBL] [Abstract][Full Text] [Related]
8. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
Moreno A; Quereda C; Montes M; Pérez-Elías MJ; Casado JL; Rodríguez-Sagrado MA; Mateos ML; Dronda F; Bárcena R; Del Campo S; Moreno S
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):e47-9. PubMed ID: 23095936
[No Abstract] [Full Text] [Related]
9. Initial results reported on raltegravir once-daily dosing.
AIDS Patient Care STDS; 2011 Feb; 25(2):123. PubMed ID: 21370546
[No Abstract] [Full Text] [Related]
10. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
11. Treatment of HIV infection with raltegravir.
Chirch LM; Morrison S; Steigbigel RT
Expert Opin Pharmacother; 2009 May; 10(7):1203-11. PubMed ID: 19385721
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral treatment update from the 17th International AIDS Conference.
Boyle B; Cohen C; DeJesus E; Elion R; Frank I; Moyle G; Sax P
AIDS Read; 2008 Nov; 18(11):570-9. PubMed ID: 19062402
[No Abstract] [Full Text] [Related]
13. Raltegravir as antiretroviral therapy in HIV/AIDS.
Sharma M; Walmsley SL
Expert Opin Pharmacother; 2014 Feb; 15(3):395-405. PubMed ID: 24304203
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
[TBL] [Abstract][Full Text] [Related]
15. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
Brainard DM; Kassahun K; Wenning LA; Petry AS; Liu C; Lunceford J; Hariparsad N; Eisenhandler R; Norcross A; DeNoia EP; Stone JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2011 Jun; 51(6):943-50. PubMed ID: 20852006
[TBL] [Abstract][Full Text] [Related]
16. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir: in treatment-naive patients with HIV-1 infection.
Croxtall JD; Scott LJ
Drugs; 2010 Mar; 70(5):631-42. PubMed ID: 20329808
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
